Endovascular Aneurysm Repair Market - Global Opportunity Analysis and Industry Forecast, 2017-2023

Endovascular Aneurysm Repair Market - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • May 2017 •
  • 190 pages •
  • Report ID: 5281614 •
  • Format: PDF
Endovascular Aneurysm Repair Market by Indication [Abdominal Aortic Aneurysm {AAA} and Thoracic Aortic Aneurysm {Ascending Aortic Aneurysm, Descending Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, and Thoracic Arch Aortic Aneurysm}], Site [Infrarenal and Pararenal {Juxtarenal and Suprarenal}], Anatomy [Traditional, and Complex], and Products [Percutaneous EVAR, Fenestrated EVAR, Aortic Stents & TAA Grafts] - Global Opportunity Analysis and Industry Forecast, 2017-2023

Endovascular aneurysm repair (EVAR) is a minimally invasive alternative to open surgery for the treatment of abdominal and thoracic aortic aneurysm. The EVAR procedure involves inserting a stent graft within the aneurysm area through a groin (femoral artery).

This stent insertion provides a permanent alternative channel for blood flow within the patient’s vasculature, thereby preventing aneurysmal sac from blood flow pressure and rupturing. This procedure is favourable for geriatric patients with arterial diseases and are unfit for major open surgeries due to reduction in risk of conventional methods and their complications.

In current scenario, the EVAR procedure is rapidly growing as a preferred treatment option compared to open surgeries for aortic aneurysm, owing to its various advantages, such as potentially improved survival rates and reduced recovery time. The global endovascular aneurysm repair (EVAR) market accounted for $2,327 million in 2016, and is anticipated to reach at $3,580 million by 2023, registering a CAGR of 6.2% from 2017 to 2023.

The factors that drive the market growth are rise in occurrences of aortic aneurysm, growth in geriatric population, technological advancements in the field of EVAR, availability of favourable reimbursements for EVAR procedures and devices, and increase in smoking population. However, the growth of the market is restricted by inflated cost associated with EVAR treatment procedures and lack of awareness among people.

Besides, EVAR also constitutes various risks associated with the procedures, such as iliac perforation, aneurysmal rupture, stent stenosis, endoleaks, and endotension. In this regard, several technologies are developed and introduced to meet such challenges leading to market growth. Moreover, the scope of improvement in the technology act as an opportunity for the market players.

The global endovascular aneurysm repair (EVAR) market is segmented based on indication, product, site, and anatomy. On the basis of indication, it is classified into abdominal aortic aneurysm (AAA) and thoracic aortic aneurysm (TAA).

The thoracic aortic aneurysm is further divided to ascending, descending, thoracoabdominal, and thoracic arch aortic aneurysm. Based on site, the market is categorised as infrarenal and pararenal. The pararenal market is bifurcated into juxtarenal and suprarenal.

In terms of anatomy, the market is classified into traditional and complex. By products, it is divided into percutaneous EVAR, fenestrated EVAR, aortic stents & thoracic aortic aneurysm (TAA) graft, and others.

Geographically, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the highest market share in the EVAR market in 2016, and is expected to maintain its dominance throughout the forecast period, owing to increase in number of EVAR procedures in U.S. For instance, as per Endologix Inc., in 2013 around 63,000 procedures of EVAR were done in U.S. Furthermore, the U.S. endograft market is growing at a CAGR of 8% per year. However, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential, owing to the improvement in healthcare facilities, available disposable income, and rapid development in the economic conditions.

The EVAR market players are nursing their product portfolio with interesting next generation and advanced technologies of their own. For instance, Lombard Medical Inc., in 2015 received Japanese Ministry of Health, Labor and Welfare (MHLW) approval for its Aorfix endovascular stent graft with the advanced AorFlex delivery system. Moreover, the company in 2016 received CE approval for its advanced IntelliFlex low profile delivery system for the aorfix endovascular stent graft.

This aorfix technology of the company is the only stent graft with global approval to treat AAA. In addition, Endlogix Inc., recently gained Food and Drug Administration (FDA) approval for its percutaneous endograft delivery system and possess a new generation Nellix technology an endovascular sealing product useful in mitigation of all types of endoleak. Hence, product development is the key strategy adopted by market players. The report provides a comprehensive analysis of the key players that operate in the global EVAR market.

The study provides an in-depth analysis of the global EVAR market and the current trends and future estimations to elucidate the imminent investment pockets.
The report presents quantitative analysis of the market from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the market based on product assists to understand the trends in the industry.
Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the industry.


By Indication
Abdominal Aortic Aneurysm (AAA)
Thoracic Aortic Aneurysm (TAA)
Ascending Aortic Aneurysm
Descending Aortic Aneurysm
Thoracoabdominal Aortic Aneurysm
Thoracic Arch Aortic Aneurysm

By Site

By Anatomy

By Products
Percutaneous EVAR
Fenestrated EVAR
Aortic Stents & TAA graft

By Geography
North America
Rest of Europe
South Korea
Rest of Asia-Pacific
Saudi Arabia
Republic of South Africa
Rest of LAMEA

Medtronic plc.
Cook Medical Inc.
Endologix, Inc.
Lombard Medical, Inc.
W. L. Gore & Associates, Inc.
Cardinal Health Inc.
C. R. Bard, Inc.
Merck & Co., Inc.
Terumo Corporation
Abbott Laboratories

The other players in the value chain include (profiles not included in the report)
Volcano Corporation
Spectranetics International BV
AbbVie Inc.
Bolton Medical Inc.
Aptus Endosystems Inc.